172
Views
11
CrossRef citations to date
0
Altmetric
Reviews

Angiogenesis-related molecular targets in esophageal cancer

, MD PhD, , MD PhD, , MD, , MD PhD, , MD, , MD PhD, , MD, , MD PhD & , MD PhD show all
Pages 637-644 | Published online: 28 Mar 2011
 

Abstract

Introduction: Angiogenesis has become an appealing target in cancer therapy due to its fundamental role in cancer growth and metastasis. A number of angiogenesis-related molecules are under investigation, with some already in clinical practice with various results. The effort to present and discuss the current status of the research on the angiogenesis-related molecular targets will lead to improved clinical strategies and outcomes for patients with esophageal cancer (EC).

Areas covered : This review summarizes the recent advances in angiogenesis-related targets in EC, and also analyzes the clinical and therapeutic applications they provide. We envisage future developments towards the anti-angiogenic strategy of molecular targets and their potential applications to cancer treatment.

Expert opinion : Angiogenesis-related targets can be used as a useful therapeutic tool for EC. More investigations should be performed to promote the success of anti-angiogenic therapy in clinical trials.

Acknowledgment

L Hong, S Li and Y Han contributed equally to this work. The authors appreciate the technical help of Prof. Genlin Ji.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.